newsfilter
← Latest News
PR Newswire·

BioVaxys Chief Medical Officer David Berd, MD, Invited by Editorial Board of Therapeutic Advances in Vaccines and Immunotherapy to Submit a Review Article on Haptenized Protein Vaccine Platform

VANCOUVER, BC, Nov. 18, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV), (FRA: 5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), a clinical-stage immunotherapy company, is pleased to announce that its Chief Medical Officer David Berd, MD, has